Announcements
- Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
- RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
- Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
- Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
- Statement of Renovaro Inc
- Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
- AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine
- Renovaro Biosciences Announces Results of Special Meeting of Shareholders
- Message from Renovaro Bioscience, Inc.’s CEO, The Hon. Mark Dybul, MD
- Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors
More ▼
Key statistics
On Friday, Renovaro Inc (2Q5:STU) closed at 1.37, 279.44% above the 52 week low of 0.36 set on Jun 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.36 |
---|---|
High | 1.37 |
Low | 1.36 |
Bid | 1.32 |
Offer | 1.45 |
Previous close | 1.35 |
Average volume | 0.00 |
---|---|
Shares outstanding | 143.67m |
Free float | 105.98m |
P/E (TTM) | -- |
Market cap | 215.50m USD |
EPS (TTM) | -0.685 USD |
Data delayed at least 15 minutes, as of May 03 2024.
More ▼